Performance Summary:

·In the first quarter of 2023, Fosun Pharma achieved operating revenue of RMB10,871 million, representing a period-on-period increase of 4.68%; net profit attributable to shareholders of the listed company after deducting extraordinary gain and loss amounted to RMB919 million, representing  a period-on-period increase of 14.78%.; net cash flow generated from operating activities amounted to RMB873 million, representing a period-on-period increase of 2.06%

·The revenue structure has experienced consistent optimization, thanks to the increased revenue generated by new and sub-new products such as HAN SI ZHUANG (Serplulimab Injection), HAN QU YOU (Trastuzumab Injection), SU KE XIN (Avatrombopag Maleate Tablets), and JIE BEI AN (Azvudine Tablets)

(April 29, 2023, Shanghai, China) On April 28, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma" or "the Group", Stock Code: 600196.SH; 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its business results for the first quarter of 2023 (the "Reporting Period").

Fosun Pharma made significant progress in the first quarter of 2023 by enhancing its independent research and development capabilities, cooperating with external organizations, expanding its product pipeline, and reinforcing its global presence. The Group achieved operating revenue of RMB10,871 million, representing a period-on-period increase of 4.68%; net profit attributable to shareholders of the listed company after deducting extraordinary gain and loss reached RMB919 million, representing a period-on-period increase of 14.78%; net cash flow generated from operating activities amounted to RMB873 million, representing a period-on-period increase of 2.06%.

Continuous Optimization of Revenue Structure with innovative products/indications approved for launch

Fosun Pharma is a patient-centered, clinical demand-oriented with innovative R&D as the core driver. Through independent R&D, cooperative development, license-in, and in-depth incubation, Fosun Pharma continued to enrich innovative product pipeline, improved the research and clinical development ability of FIC (First-in-class) and BIC (Best-in-class) new drugs, and accelerated the research, development, and transformation of innovative technologies and products.

In the first quarter of 2023, the revenue structure of Fosun Pharma has experienced consistent optimization, thanks to the increased revenue generated by new and sub-new products such as HAN SI ZHUANG (Serplulimab Injection), HAN QU YOU (Trastuzumab Injection), SU KE XIN(Avatrombopag Maleate Tablets), and JIE BEI AN (Azvudine Tablets).

Furthermore, Fosun Pharma focuses on core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease). Fosun Pharma continued to increase its investment in innovative R&D and several new products and indications have been approved for launch during Q1 2023, among which, HAN SI ZHUANG (Serplulimab Injection), the first self-developed biopharmaceutical innovative drug of the Group, has been approved for an additional indication, i.e. extensive-stage small cell lung cancer (ES-SCLC), indicating that Han Si Zhuang has become the world’s first monoclonal antibody drug targeting PD-1 approved for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), and its marketing authorization application (MAA) in the EU has also been accepted.

Keverprazan Hydrochloride tablets (trade name: Bei Wen), the first potassium ion competitive acid blocker (P-CAB) independently developed in China, jointly developed by Fosun Pharma and Jiangsu Carephar Pharmaceutical Co., Ltd.* and exclusively commercialized by the Group, was approved for launch in Chinese mainland (excluding Hong Kong, Macau and Taiwan, China, the same below) for the treatment of duodenal ulcer (DU) and reflux esophagitis (RE).

Quickening the Introduction of Diverse Innovative Products from Independent R&D and License-in

Throughout the Reporting Period, Fosun Pharma has made significant progress in the clinical and approval stages of several independently developed and licensed-in products. Notably, the medication administration for the first patient in the phase III of the international multi-center clinical study of HAN SI ZHUANG (Serplulimab Injection) for its efficacy in treating limited-stage small cell lung cancer (LS-SCLC) in combination with chemotherapy and radiation therapy has been completed in the United States. HAN QU YOU (Trastuzumab Injection), the first domestic monoclonal antibody biosimilar, has received approval for launch in both Chinese and European markets. Its biologics license application (BLA) has been accepted by the Food and Drug Administration (FDA) of the United States, indicating that it could potentially become the first domestically produced biosimilar to be approved in China, the European Union, and the United States. With this development, HAN QU YOU aims to expand its business in the mainstream biopharmaceutical markets of Europe and the United States. In April 2023, the enrollment of the Phase III clinical trial of the 13-valent pneumococcal conjugate vaccines (multivalent combinations) has been finished in China. Additionally, the FCN-159 for the treatment of histiocytic tumors has been included in the Breakthrough Therapy Drug Program by the National Medical Products Administration in April 2023.

Moreover, FS-1502 (Recombinant HER2 Humanized Monoclonal Antibody-monomethyl Auristatin F Conjugate for Injection), the licensed-in innovator drug by Fosun Pharma for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer, has undergone the Phase III clinical study in China during the Reporting Period. HLX208 (BRAF V600E Inhibitor) for the treatment of BRAF V600E mutated langerhans cell histiocytosis (LCH) in adults and Erdheim-Chester disease (ECD) has been included in the Breakthrough Therapy Drug Program by the National Medical Products Administration in April 2023. The new drug application in Chinese mainland of RT002 (DaxibotulinumtoxinA) for the temporary improvement of moderate to severe glabellar lines in adults caused by corrugator supercilii and/or procerus muscle activity has been accepted in April 2023.

Enhancing International Cooperation and Continuously Strengthening Global Operational Capability

Fosun Pharma prioritizes both independent innovation and open cooperation. We actively pursue partnerships with globally recognized enterprises. In Q1 2023, Sisram Medical Ltd (‘‘Sisram Medical’’), a subsidiary, entered into an agreement with PhotonMed International Limited, based on which Sisram Medical proposed to control the brand and channels of ‘‘Alma’’ through merger and acquisition of assets, so as to achieve a direct sales layout in the Chinese market for the energy source medical beauty equipment business and enhance the brand awareness on the user end.

In April 2023, Gland Pharma Limited, a subsidiary, completed the acquisition of Cenexi (i.e. Phixen, société par actions simplifiée), a European CDMO company, so as to strategically establish its CDMO business presence in the European market and build up local manufacturing capabilities in Europe.

Additionally, Fosun Pharma leverages its strong two-way licensing capabilities to strategically enhance commercial development and widen the reach of its key products in core regional markets. Shanghai Henlius, a subsidiary of Fosun Pharma, has entered into a licensing and supply agreement with Boston Oncology, LLC (‘‘Boston Oncology’’). As per the agreement, Boston Oncology has been granted exclusive rights for developing and commercializing Rituximab Injection in 16 emerging markets across Asia and Africa. This move is aimed at increasing the availability and accessibility of such product in these regions.

In the future, Fosun Pharma is committed to following the 4IN strategy, which involves focusing on Innovation, Internationalization, Intelligentization, and Integration. In line with this, we will adopt a development pattern that prioritizes "Innovation and Transformation, Integrated Operation, and Steady Growth," with a strong emphasis on creating value for our shareholders. To advance our objectives, we will enhance our independent R&D capabilities, while also expanding our external collaborations. Our aim is to enrich our product pipelines, bolster our global presence, optimize our operational efficiency, and accelerate the development and commercialization of more exceptional products. We will strive to develop a variety of innovative solutions, both FIC (First-in-class) and BIC (Best-in-class), to meet the needs of our customers.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products.

Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

For more information, please visit our official website: www.fxcprm.com